{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Percentage of participants with Complete Response (CR), Partial Response (PR), or stable disease (SD) lasting at least 8 weeks from the first administration of study drug. RECIST guidelines:(Response evaluation criteria in solid tumors, version 1.0).","groups":[{"description":"AZD4877 25 mg (Intravenous (IV), 25mg weekly)","id":"OG000","title":"AZD4877"}],"paramType":"NUMBER","populationDescription":"Of the 41 participants who received at least one dose of study medication, only 39 were evaluable for response by RECIST (excludes 2 patients who had baseline scans performed more than 28 days before dosing).","reportingStatus":"POSTED","timeFrame":"8 weeks after study drug begins & every 8 weeks thereafter until discontinuation of the study ( maximum treatment period of 309 days (44 weeks)","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}